Investing.com - Financial Markets Worldwide

Repare Therapeutics Inc (RPTX)

NASDAQ
Currency in USD
1.340
+0.010(+0.75%)
Closed·
After Hours
1.359+0.019(+1.418%)
·
RPTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
RPTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
1.3101.350
52 wk Range
0.8904.290
Key Statistics
Edit
Prev. Close
1.34
Open
1.32
Day's Range
1.31-1.35
52 wk Range
0.89-4.29
Volume
181.45K
Average Volume (3m)
310.96K
1-Year Change
-62.25%
Book Value / Share
2.94
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RPTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Sell
Analysts Sentiment
Buy
Price Target
6.500
Upside
+385.07%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 9
2 analysts have revised their earnings upwards for the upcoming period
Unlock InvestingPro

Repare Therapeutics Inc News & Analysis

Show more

Repare Therapeutics Inc Company Profile

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
129
Market
United States

Compare RPTX to Peers and Sector

Metrics to compare
RPTX
Peers
Sector
Relationship
P/E Ratio
−0.4x−3.8x−0.5x
PEG Ratio
0.00−0.010.00
Price/Book
0.5x0.3x2.6x
Price / LTM Sales
53.1x8.8x3.0x
Upside (Analyst Target)
385.1%376.2%54.1%
Fair Value Upside
Unlock13.8%8.7%Unlock

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.500
(+385.07% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.71 / -0.63
Revenue / Forecast
-- / 1.94M
EPS Revisions
a
a
Unlock
Last 90 days

People Also Watch

Exelixis
45.40
EXEL
-1.86%
Verve Therapeutics
4.63
VERV
+7.18%
Halozyme
52.02
HALO
+6.27%
Teradyne
82.73
TER
-0.31%
Deckers Outdoor
127.91
DECK
+0.76%

FAQ

What Stock Exchange Does Repare Trade On?

Repare is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Repare?

The stock symbol for Repare is "RPTX."

What Is the Repare Market Cap?

As of today, Repare market cap is 56.96M.

What Is Repare's Earnings Per Share (TTM)?

The Repare EPS (TTM) is -3.01.

When Is the Next Repare Earnings Date?

Repare will release its next earnings report on 05 Aug 2025.

From a Technical Analysis Perspective, Is RPTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.